NP_009148.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
24,702 Da
NCBI Official Full Name
programmed cell death protein 10
NCBI Official Synonym Full Names
programmed cell death 10
NCBI Official Synonym Symbols
NCBI Protein Information
programmed cell death protein 10
UniProt Protein Name
Programmed cell death protein 10
UniProt Synonym Protein Names
Cerebral cavernous malformations 3 protein; TF-1 cell apoptosis-related protein 15
UniProt Synonym Gene Names
NCBI Summary for PDCD10
This gene encodes an evolutionarily conserved protein associated with cell apoptosis. The protein interacts with the serine/threonine protein kinase MST4 to modulate the extracellular signal-regulated kinase (ERK) pathway. It also interacts with and is phosphoryated by serine/threonine kinase 25, and is thought to function in a signaling pathway essential for vascular developent. Mutations in this gene are one cause of cerebral cavernous malformations, which are vascular malformations that cause seizures and cerebral hemorrhages. Multiple alternatively spliced variants, encoding the same protein, have been identified. [provided by RefSeq, Jul 2008]
UniProt Comments for PDCD10
PDCD10: Promotes cell proliferation. Modulates apoptotic pathways. Increases mitogen-activated protein kinase activity and MST4 activity. Important for cell migration, and for normal structure and assembly of the Golgi complex. Important for KDR/VEGFR2 signaling. Increases the stability of KDR/VEGFR2 and prevents its breakdown. Required for normal cardiovascular development. Required for normal angiogenesis, vasculogenesis and hematopoiesis during embryonic development. Defects in PDCD10 are the cause of cerebral cavernous malformations type 3 (CCM3). Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. Belongs to the PDCD10 family.
Protein type: Apoptosis
Chromosomal Location of Human Ortholog: 3q26.1
Cellular Component: cytoplasm; cytosol; Golgi apparatus
Molecular Function: protein binding; protein homodimerization activity; protein kinase binding; protein N-terminus binding
Biological Process: establishment of Golgi localization; negative regulation of apoptosis; positive regulation of cell migration; positive regulation of cell proliferation; positive regulation of MAP kinase activity; positive regulation of Notch signaling pathway; positive regulation of peptidyl-serine phosphorylation; positive regulation of stress-activated MAPK cascade; protein stabilization; regulation of Rho protein signal transduction; response to hydrogen peroxide; stress fiber formation
Disease: Cerebral Cavernous Malformations 3
Research Articles on PDCD10
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-PDCD10 antibody
Pathways associated with anti-PDCD10 antibody
Diseases associated with anti-PDCD10 antibody
Organs/Tissues associated with anti-PDCD10 antibody
|